Side-by-side comparison of AI visibility scores, market position, and capabilities
NYC healthcare AI clinical insights at $350M valuation Jul 2024 with 3M+ diagnoses surfaced and $50M+ incremental revenue for partners; $81.3M total ($61M Oak HC/FT Series B) serving Banner Health and Sentara competing with Nuance CDI.
Regard is a New York-based healthcare AI company — backed with $81.3 million in total funding including a $61 million Series B in July 2024 led by Oak HC/FT with Cedars-Sinai Health Ventures at a $350 million valuation, following a $15.3 million Series A in 2022 and $5 million seed in 2021 — providing health systems with an AI clinical insights platform that analyzes 100% of hospitalized patient medical record data to surface missed diagnoses to care teams, acting as an AI co-pilot for physicians that has surfaced 3 million+ diagnoses and generated $50+ million in incremental revenue for health system partners through improved documentation accuracy. Founded in 2019 by Eli Ben-Joseph, Nate Wilson, and Thomas Moulia (Stanford graduate students) and launched in 2021, Regard serves major health systems including Banner Health (33 acute care hospitals) and Sentara Health (12 hospitals).
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.